Table 1. Association between PRDX2 expression and clinicopathologic characteristics of CRC patients in the study cohort.
| Characteristics | No. of patients (%) | PRDX2 expression | P value | |
|---|---|---|---|---|
| Low (%) | High (%) | |||
| (n = 226) | (n = 97) | (n = 129) | ||
| Age (years) | 0.412 | |||
| < 60 | 84(37.2%) | 39(40.2%) | 45(34.9%) | |
| ≥ 60 | 142(62.8%) | 58(59.8%) | 84(65.1%) | |
| Sex | 0.833 | |||
| Female | 109(48.2%) | 46(47.4%) | 63(48.8%) | |
| Male | 117(51.8%) | 51(52.6%) | 66(51.2%) | |
| Tumor location | ||||
| Colon | 119(52.7%) | 53(54.6%) | 66(51.2%) | 0.604 |
| Rectum | 107(47.3%) | 44(45.4%) | 63(48.8%) | |
| Tumor size (cm) | 0.471 | |||
| < 5 | 90(39.8%) | 36(37.1%) | 54(41.9%) | |
| ≥ 5 | 136(60.2%) | 61(62.9%) | 75(58.1%) | |
| Bowel obstruction/perforation | 0.644 | |||
| No | 216(95.6%) | 92(94.8%) | 124(96.1%) | |
| Yes | 10(4.4%) | 5(5.2%) | 5(3.9%) | |
| Differentiation grade | 0.001 | |||
| Well | 18(8.0%) | 12(12.4%) | 6(4.7%) | |
| Moderate | 144(63.7%) | 69(71.1%) | 75(58.1%) | |
| Poor | 64(28.3%) | 16(16.5%) | 48(37.2%) | |
| Serum CEA level (ng/mL) | 0.629 | |||
| < 10 | 103(45.6%) | 46(47.4%) | 57(44.2%) | |
| ≥ 10 | 123(54.4%) | 51(52.6%) | 72(55.8%) | |
| Local invasion | 0.046 | |||
| T1–T2 | 44(19.5%) | 13(13.4%) | 31(24.0%) | |
| T3–T4 | 182(80.5%) | 84(86.6%) | 98(76.0%) | |
| Lymph node metastasis | 0.008 | |||
| N0 | 120(53.1%) | 59(60.8%) | 61(47.3%) | |
| N1 | 84(37.2%) | 35(36.1%) | 49(38.0%) | |
| N2 | 22(9.7%) | 3(3.1%) | 19(14.7%) | |
| TNM stage | 0.020 | |||
| I | 17(7.5%) | 12(12.4%) | 5(3.9%) | |
| II | 103(45.6%) | 47(48.5%) | 56(43.4%) | |
| III | 106(46.9%) | 38(39.2%) | 68(52.7%) | |
Abbreviations: CEA, carcinoembryonic antigen; PRDX2, peroxiredoxin 2; TNM, tumor-node-metastasis.